glenmark pharmaceuticals - Latest News, Analysis, Opinion - BW Businessworld

Latest Articles in glenmark pharmaceuticals

Glenmark Slashes Cost Of Breast Cancer Drug Trastuzumab In India

Glenmark Pharmaceuticals, the global pharmaceutical company on Thursday restructured the price of Trastuzumab drug indicated for HER2‐positive breast cancer. A 440 mg vial of Trumab will be priced at Rs 15,749, which makes it the most affordable option available currently in the country, the company said in a statement

Glenmark Pharma Registers Lower Q4 Profit On Account Of One-Off Expense

BW Online Bureau

Economy

Consolidated profit before exceptional items and tax fell to Rs 309 crores for the three months ended March 31, from Rs 352 crores billion a year earlier, the cetirizine maker said in a stock exchange filing

Glenmark Pharma Gets USFDA Nod For Generic Drug For Schizophrenia

BW Online Bureau

Economy

Mumbai-based Glenmark Pharmaceuticals has received final approval by the United States Food and Drug Administration (U.S. FDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine Tablets, 5 mg and 10 mg, of GlaxoSmithKline

Glenmark Pharma Receives Approval For Clindamycin Hydrochloride Capsules

BW Online Bureau

Economy

Glenmark Pharmaceuticals has received final approval from the United States Food and Drug Administration (U.S. FDA) for Clindamycin Hydrochloride Capsules USP, 75 mg, 150 mg, and 300 mg, the generic version of Cleocin Hydrochloride Capsules, 75 mg, 150 mg, and 300 mg, of Pfizer Inc

Q3 Results: Glenmark's PAT Dips By 1.2% QoQ, Revenue At Rs 540 Cr

Shivam Tyagi

Economy

Glenmark Pharmaceuticals recorded a net profit of Rs 105 crores in quarter three of the financial year 2023(Q3FY23) against Rs 103.7 crores recorded in the corresponding quarter in the previous year, a 1.2 per cent jump year on year while the PAT dropped by 1.2 per cent quarter on quarter

Glenmark's Baddi Facility To Supply Atovaquone To US On Exception: USFDA

BW Online Bureau

Economy

Mumbai-based pharmaceutical company Glenmark on Friday said that its manufacturing facility in Baddi which was earlier kept under the import alert list by the USFDA in October 2022, will now be supplying Atovaquone Oral Suspension USP 750mg/5 to the US market as per the latest communication received by the company from the top US regulator

Glenmark Unveils Drug For Heart Failure Treatment In India

BW Online Bureau

Economy

The sacubitril-valsartan combination belongs to the class ARNI (Angiotensin receptor neprilysin inhibitor). These molecules have two therapeutic targets in the treatment of heart failure: 1) the natriuretic peptide (NP) system for sacubitril and the 2) Renin Angiotensin System (RAS) for valsartan

Glenmark Pharmaceuticals Receives USFDA Approval For Nicardipine Hydrochloride Capsules

BW Online Bureau

Economy

According to IQVIATM sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market2 achieved annual sales of approximately USD 10.9 million, the statement by the company stated

Glenmark Pharma Launches FDC Drug For Uncontrolled Asthama

BW Online Bureau

Health

Purulia recorded 30 mm rainfall in 24 hours till 8.30 am on Thursday as other parts of Gangetic West Bengal largely remained dry

Glenmark To Conduct Clinical Trials Of Its Molecule On Cancer Patients

BW Online Bureau

Companies & Markets

Glenmark Pharmaceuticals said its unit has received approval from the DCGI to conduct phase 1 clinical trials of its novel molecule on patients with advanced solid tumors

Glenmark Pharmaceuticals Receives ANDA Approval For Bisoprolol Fumarate & Hydrochlorothiazide Tablets

BW Online Bureau

Economy

The company's current portfolio consists of 172 products authorised for distribution in the US marketplace and 46 ANDA’s pending approval with the US FDA.

Glenmark Life Sciences IPO To Open Next Week

BW Online Bureau

Health

Glenmark Life Sciences had filed the red herring prospectus for the offer with the Registrar of Companies, Pune and it was taken on record by the ROC the next day, Glenmark Pharma said in a BSE filing.